NCT00505063CompletedPhase 2
Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Phase II Prospective Trial of Vaccine Responses in Childhood Cancer Survivors
Source: ClinicalTrials.gov · Last updated 29 Jul 2026
Brief summary (registry, in English)
This study will look at your body's response to the new immunizations. We want to see how well they will protect you. Immunization is the same as vaccination. Our goal is to protect you as much as we can. We do not want you to have the measles, mumps, or whooping cough. We are doing the study because there is no standard way to re-immunize people after cancer treatments.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 75 (actual)
- First submitted
- 18 Jul 2007
- Start date
- 10 Jul 2007
- Primary completion date
- 11 Jun 2025
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Childhood cancers
- NCT number
- NCT00505063
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 75
- From 10 Jul 2007 to the primary completion date, 11 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients who have received an autologous or allogeneic HCT.
- Patients who have a history of previous allergic reaction to vaccinations currently recommended by the ACIP.
- Patients on any immunosuppressive drugs.
- Patients with prior allergic reaction to any vaccine component or to latex.
- Patients who have received Rituximab.
Other illness
- Active uncontrolled bacterial or fungal infection.
- HIV-1,2 sero-positive patients.
Other
- Karnofsky score \<70%.
- Female patients who are pregnant or lactating.
- Patients or guardians not signing informed consent.
Who the study is looking for
- Patient must be \< or less 18 years of age at cancer diagnosis
- Patient must be 3 to 24months following completion of chemotherapy for malignant disease.
- For patients \<12 months following completion of therapy, CR must be documented within 3 months of enrollment.
- For patients \>12 months, CR must be documented at approximately 12 months and then only as clinically indicated
- For patients with leukemia: bone marrow aspirate defined as \<5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable) and no evidence of CSF involvement (if applicable) ii. For patients with solid tumors remission will be determined by appropriate radiologic scans, and other tests, including bone marrow aspirate and biopsies demonstrating absence of extrinsic cells and absence of specific FISH or cytogenetic abnormality (if applicable), iii. For patients with lymphoma, remission will be determined by bone marrow aspirate and biopsy, radiologic scans and other tests. Bone marrow will show \<5% blasts, absence of cytogenetic abnormality by FISH or karyotype (if applicable), and flow cytometry (if lymphoma specific marker present) and absence of CNS disease by spinal fluid (if applicable)
- Patient may be of either gender and of any ethnic background
- Patients or their guardians must be able to understand the nature and risk of the proposed study and be able to sign consent.
Age in the registry: 2 years to 18 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.